How much Ponatinib daily for CML/Ph ALL?

Ponatinib is an inhibitor that’s used for treating chronic myeloid leukemia (CML) and a type of ALL called Ph ALL. It’s for people whose disease has been resistant to previous treatments like tyrosine kinase inhibitors. It zeroes in on a specific thing called the BCR-ABL fusion protein, and also hits a few other spots that help cancer keep growing and spreading.

There are two doses available for ponatinib: you’ve got 15 mg and 45 mg versions, both in these film-coated tablets. They usually tell you to take the 45 mg tablet just once a day, whether you eat or not. Each bottle holds a 30-tablet supply.